



**Governing Council
Sixty-seventh Session**

GC/67/17
2 April 2025

Lyon, 6–8 May 2025
Hybrid format

APPOINTMENT OF NEW MEMBERS OF THE SCIENTIFIC COUNCIL

- In accordance with Article VI of the Statute and Resolution GC/63/R12, the term of office of six members of the Scientific Council, namely Drs Walter Berger (Austria), Luis Felipe Ribeiro Pinto (Brazil), Marie-Elise Parent (Canada), Jie He (China), Mathilde Touvier (France) and Einas Abdulaziz Eid Al Kuwari (Qatar) will be completed with the 2025 meeting of the Governing Council.
- Professor Jeannette Falck Winther (Denmark) resigned from membership of the Scientific Council. According to Article VI. Para. 3 of the Statute of the Agency, a new appointment should be made for the remainder of her term, i.e. until 2026.
- For the information of the Council, this leaves the following 21 members (4 women and 17 men) still serving on the Scientific Council: Drs Satish Gopal (USA), Sirpa Heinävaara (Finland), Valery Lemmens (Netherlands) and Ben Spycher (Switzerland) until 2026; and Drs Mohamed Berraho (Morocco), Valeriy V Breder (Russian Federation), Roberta De Angelis (Italy), David Gisselsson Nord (Sweden), André Karch (Germany), István Kenessey (Hungary), Young-Woo Kim (Republic of Korea), Prashant Mathur (India), Pål Romundstad (Norway) and Orla Shiels (Ireland) until 2027; and Drs Adam Grant Elshaug (Australia), Eric Van Cutsem (Belgium), Hesham Elghazaly (Egypt), Tatsuhiko Shibata (Japan), Ali Saeed Al-Zahrani (Saudi Arabia), María José Sánchez Pérez (Spain) and Richard Sullivan (United Kingdom) until 2028.
- The areas of expertise of those members remaining on the Scientific Council are provided below for consideration by the Governing Council in making its selection of new Scientific Council members from among the nominations.

Name	Country	Term of office	Gender	Field of expertise
Einas Abdulaziz Eid Al Kuwari	Qatar	2022 – 2025	F	Pathology and laboratory medicine
Walter Berger	Austria	2022 – 2025	M	Systemic cancer therapy with a focus on primary brain tumours, thoracic malignancies and sarcomas 1) Identification of novel therapeutic molecular targets and the respective inhibitors 2) Development of tumour-targeted small molecule anticancer agents 3) Dissection of drug resistance mechanisms and development of circumvention approaches

Name	Country	Term of office	Gender	Field of expertise
Jie He	China	2022 – 2025	M	Thoracic cancer surgery, translational research of thoracic cancers
Marie-Elise Parent	Canada	2022 – 2025	F	Cancer epidemiology, with a focus on the etiological role of occupational, environmental and lifestyle factors
Luis Felipe Ribeiro Pinto	Brazil	2022 – 2025	M	Mechanisms of carcinogenesis; molecular epidemiology; epigenetics and somatic mutations in relation to etiological factors; developing biomarkers of early detection or targeted therapies in upper aerodigestive tract tumours
Mathilde Touvier	France	2022 – 2025	F	Epidemiology; nutrition and cancer
Jeanette Falck Winther	Denmark	2023 – 2026	F	Cancer treatment in survivors of childhood cancer; molecular/genetic profiles; radiation; familial cancer syndromes (neurofibromatosis type 1) affecting children.
Satish Gopal	USA	2023 – 2026	M	Lymphoid malignancies; HIV-associated malignancies; low- and middle-income countries; clinical/translational research; cancer epidemiology; outcomes research.
Sirpa Heinävaara	Finland	2023 – 2026	F	Statistics, modelling systems, cancer mortality, screening strategies, radiation epidemiology.
Valery Lemmens	The Netherlands	2023 – 2026	M	Cancer epidemiology; Cancer registration; Public health; Implementation science; Social inequalities; Global statistics.
Ben Spycher	Switzerland	2023 – 2026	M	Biostatistics, epidemiology, childhood cancer, environmental exposures.
Mohamed Berraho	Morocco	2024 – 2027	M	Cancer Epidemiology, epidemiology of cervical cancer, epidemiology of noncommunicable diseases (diabetes and hypertension), Epidemiology of NCD risk factors, mental health, occupational health.
Valeriy V. Breder	Russian Federation	2024 – 2027	M	Liver cancer: screening, early diagnosis, cancer treatment. Lung cancer: chemotherapy, immunotherapy, targeted therapy.
Roberta De Angelis	Italy	2024 – 2027	F	Descriptive and analytical cancer epidemiology; cancer registries; biostatistics; statistical methods to derive cancer burden and outcome indicators from population-based data.

Name	Country	Term of office	Gender	Field of expertise
David Gisselsson Nord	Sweden	2024 – 2027	M	Genomics, childhood cancer, implementation of precision medicine, computational carcinogenesis, laboratory establishment in low-income countries.
André Karch	Germany	2024 – 2027	M	Causal inference in observational research, mammography screening, breast cancer, clinical epidemiology, biomarkers, statistical and epidemiological methods.
István Kenessey	Hungary	2024 – 2027	M	Epidemiology of cancer, cancer survivorship and the effect of advanced oncological therapies.
Young-Woo Kim	Republic of Korea	2024 – 2027	M	Surgical oncology (gastric cancer); translational research (proteogenomics and drug development); medical engineering for surgical device development and patient blood management.
Prashant Mathur	India	2024 – 2027	M	Noncommunicable diseases, epidemiology and surveillance (including cancer), cancer registrations, cancer risk reduction strategies.
Pål Richard Romundstad	Norway	2024 – 2027	M	Cancer epidemiology, reproductive epidemiology, mendelian randomization, life course and intergenerational studies.
Orla Sheils	Ireland	2024 – 2027	F	Molecular pathology; molecular diagnostic assays; translational research; virally driven cancers; cancer prevention, detection, diagnosis, and treatment.

5. In accordance with Article VI.2 of the Agency’s Statute, the Governing Council is requested to select new members to be appointed to the Scientific Council from the attached list of experts, one each from Austria, Brazil, Canada, China, Denmark, France and Qatar.

<p>AUSTRIA</p> <p>Professor Eva Schernhammer Medical University Vienna</p> <p>Field: Lifestyle, diet, and environmental risk factors to chronic diseases and longevity in humans; etiology and prevention of gastrointestinal tumors.</p>	<p>BRAZIL</p> <p>Dr Mariana Emerenciano Cavalcanti de Sá Senior Researcher. Research and Innovation Coordination. Brazilian National Cancer Institute - INCA.</p> <p>Field: Genetics and Molecular Biology of Cancer; hematological neoplasms.</p>
--	---

<p>CANADA Dr Rayjean Hung Associate Director of Population Health, Lunenfeld-Tanenbaum Research Institute, Canada</p> <p>Field: Cancer epidemiology; cancer etiology, early detection, prognosis; aerodigestive tract cancers and pediatric tumours; risk prediction modelling; multi-modal data elements and data harmonization; Omics discovery; policy implementation.</p>	<p>CHINA <i>Yet to be received</i></p>
<p>DENMARK</p> <p>Professor Henrik Hjalgrim Danish Cancer Institute (DCI), Danish Cancer Society, Copenhagen, Denmark</p> <p>Field: Haematology, Childhood oncology, pathology and immunology; epidemiology, biostatistics, genetics, and bioinformatics; prenatal and early life exposures, e.g., infections, and immune-related conditions in childhood cancers and haematological malignancies.</p>	<p>FRANCE</p> <p>Professor Geneviève Almouzni UMR3664 CNRS-Institut Curie, Paris, France</p> <p>Fields : Chromatin biology in development and disease; pneumology; genetics and epigenetics.</p> <p style="text-align: center;">***</p> <p>Professor Robert Barouki Institut pour la Recherche en Santé Publique</p> <p>Fields : Biochemistry, molecular biology; chemical toxicants exposure, genotoxicity; pollutants and cancer.</p>
<p>QATAR</p> <p>Professor Mohamed Ussama Alomsi Qatar National Center for Cancer Care & Research</p> <p>Fields: Hematology and oncology; lung cancer, head and neck cancer, and genitourinary cancer.</p>	

NB: The *curricula vitae* will be distributed to Governing Council members only.